- Merck KGaA Drops Heart Drug After Novartis Trial Failure Raises Concerns
Merck KGaA plans to drop an experimental heart drug it’s acquiring through the takeover of Silence Therapeutics Plc in the wake of the failure of a similar treatment by rival Novartis AG.
Product·1 article / 1 outlet·4d ago
- Novartis Heart Drug Trial Fails to Show Cardiovascular Benefits Despite Lowering Lp(a) Levels
A closely watched clinical trial for a Novartis heart drug revealed that it had no cardiovascular benefit, even though it reduced Lp(a) levels. The failure of this trial raises questions about the effectiveness of similar therapies being developed by rivals.
Product·2 articles / 2 outlets·7d ago
- Novartis Reports Nine Cancer Cases Possibly Linked to Gene Therapy Zolgensma
Novartis has revealed that nine recipients of its gene therapy Zolgensma have developed cancer, raising concerns about the treatment's safety. This includes two cases that involved tumors, highlighting potential risks associated with AAV gene therapies for spinal muscular atrophy (SMA) patients.
Product·2 articles / 2 outlets·10d ago
- Novartis Reports Nine Cancer Cases Possibly Linked to Gene Therapy Zolgensma
Novartis has revealed the occurrence of cancer in nine recipients of its gene therapy Zolgensma, raising concerns about potential risks associated with the treatment. This includes two cases that involved tumors, highlighting the need for caution among SMA patients and gene therapy researchers.
Product·2 articles / 2 outlets·10d ago
- Novartis Reports Nine Cancer Cases Possibly Linked to Gene Therapy Zolgensma
Novartis has revealed that there have been nine cases of cancer in recipients of its gene therapy Zolgensma, raising concerns about the potential risks associated with the treatment. This development highlights the tumor risks associated with AAV gene therapies, which is significant for patients with spinal muscular atrophy (SMA) and gene therapy researchers.
Product·2 articles / 2 outlets·10d ago
- Novartis Reports Nine Cancer Cases Possibly Linked to Gene Therapy Zolgensma
Novartis has revealed that there have been cancer occurrences in nine recipients of its gene therapy Zolgensma, raising concerns about the treatment's safety. This includes two cases that involved tumors, highlighting potential risks associated with AAV gene therapies for spinal muscular atrophy (SMA) patients.
Product·2 articles / 2 outlets·10d ago
- Novartis Reports Nine Cancer Cases Possibly Linked to Gene Therapy Zolgensma
Novartis has revealed that nine recipients of its gene therapy Zolgensma have developed cancer, raising concerns about the treatment's safety. This development highlights potential tumor risks associated with AAV gene therapies, which could impact patients with spinal muscular atrophy (SMA) and the broader gene therapy research community.
Product·2 articles / 2 outlets·10d ago
- Novartis Reports Nine Cancer Cases Possibly Linked to Gene Therapy Zolgensma
Novartis has revealed the occurrence of cancer in nine recipients of its gene therapy Zolgensma, raising concerns about potential risks associated with the treatment. This development highlights the tumor risks associated with AAV gene therapies, which may impact patients with spinal muscular atrophy (SMA) and gene therapy research as a whole.
Product·2 articles / 2 outlets·10d ago
- Novartis Reports Nine Cancer Cases Possibly Linked to Gene Therapy Zolgensma
Novartis has revealed that there have been nine cases of cancer in recipients of its gene therapy Zolgensma, raising concerns about potential risks associated with the treatment. This development highlights the tumor risks associated with AAV gene therapies, which is significant for patients with spinal muscular atrophy (SMA) and researchers in the field.
Product·2 articles / 2 outlets·10d ago
- Novartis Reports 7 Tumor Cases Linked to SMA Gene Therapy Zolgensma
Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, Zolgensma.
Product·2 articles / 2 outlets·10d ago
- Novartis Reports Nine Cancer Cases Possibly Linked to Gene Therapy Zolgensma
Novartis has revealed the occurrence of cancer in nine recipients of its gene therapy Zolgensma, raising concerns about potential risks associated with the treatment. Two of these cases involved tumors, highlighting the need for further investigation into the safety of AAV gene therapies for patients with spinal muscular atrophy (SMA).
Product·2 articles / 2 outlets·10d ago
- Novartis Reports Nine Cancer Cases Possibly Linked to Gene Therapy Zolgensma
Novartis has revealed that there have been nine cases of cancer in recipients of its gene therapy Zolgensma, raising concerns about potential risks associated with the treatment. This development highlights the tumor risks associated with AAV gene therapies, which could impact patients with spinal muscular atrophy (SMA) and the broader gene therapy research community.
Product·2 articles / 2 outlets·10d ago